Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
| Pharmaceuticals Industry | Healthcare Sector | Joseph T. Morrissey Jr. CEO | LSE Exchange | 68622V106 CUSIP |
| US Country | 10,000 Employees | 11 Jun 2026 Last Dividend | - Last Split | 2 Jun 2021 IPO Date |
Organon & Co. is a healthcare company focused on innovating and providing a range of health solutions specifically tailored towards women's health needs both in the United States and globally. The company's diverse product offering encompasses a variety of prescription therapies and medical devices. Founded in 2020 and headquartered in Jersey City, New Jersey, Organon & Co. has quickly positioned itself as a key player in women's health, extending its reach through a broad spectrum of contraception and fertility treatments, biosimilars, and other healthcare solutions. Their mission extends to addressing critical areas such as cardiovascular health, respiratory conditions, dermatology, bone health, and non-opioid pain management, catering to a wide demographic. Through its commitment to health innovation, Organon & Co. markets its products to a vast network of stakeholders including drug wholesalers, retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions.